388 related articles for article (PubMed ID: 31551292)
1. Emerging glucose-lowering therapies: a guide for cardiologists.
Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
[TBL] [Abstract][Full Text] [Related]
2. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
3. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
5. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
[TBL] [Abstract][Full Text] [Related]
6. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
[TBL] [Abstract][Full Text] [Related]
7. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.
Hamid A; Vaduganathan M; Oshunbade AA; Ayyalasomayajula KK; Kalogeropoulos AP; Lien LF; Shafi T; Hall ME; Butler J
J Cardiovasc Pharmacol; 2020 Sep; 76(3):313-320. PubMed ID: 32569016
[TBL] [Abstract][Full Text] [Related]
8. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):422-427. PubMed ID: 31064213
[TBL] [Abstract][Full Text] [Related]
10. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
Pagidipati NJ; Lopes RD
J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
[No Abstract] [Full Text] [Related]
11. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
12. New anti-diabetic agents: major advances with unanswered questions.
Sabouret P; Bocchino PP; Biondi-Zoccai G
Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
[TBL] [Abstract][Full Text] [Related]
13. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
Ludwig L; Darmon P; Guerci B
Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
[TBL] [Abstract][Full Text] [Related]
14. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
Tanaka A; Node K
Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
Heuvelman VD; Van Raalte DH; Smits MM
Cardiovasc Res; 2020 Apr; 116(5):916-930. PubMed ID: 31825468
[TBL] [Abstract][Full Text] [Related]
18. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
Testani JM; Inzucchi SE; Voors AA
Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
[No Abstract] [Full Text] [Related]
19. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
20. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
